The patent for the phenomenal Sitagliptin, known as the brand name Januvia, is set to expire on April 24, 2017. As a blockbuster drug sitagliptin, CAS number 486460-32-6, is set up for undoubted success as a generic drug. Sales of Januvia in both the United States and Japan are extremely strong, so much so that Merck’s best-selling pharmaceutical product is Januvia. Results from 2012 financials revealed Januvia enjoyed a 23 percent year-to-year sales boost, to almost $4.1 billion in the 2012 calendar year. The fourth quarter sales of Januvia climbed 18 percent, to $1.1 billion dollars, as compared to $960 million dollars in the last quarter of 2011.
As a medication designed to help patients with type 2 diabetes control their blood sugar levels, sitagliptin works by regulating insulin levels of patients. Sitagliptin is offered as Januvia is dosages of 25 milligrams, 50 milligrams and 100 milligram tablets. With almost 95 percent of the diabetic patients in the United States diagnosed with type 2 diabetes, roughly one out of ten American adults has the treatable and controllable form of this disease. The future picture of type 2 diabetes in the U.S. is not reassuring either, as predicted by the Centers for Disease Control, or CDC. The CDC estimates that by 2050 a staggering one out of every three adults in the United States may be suffering from diabetes, based on current medical trends. These future diagnoses will strain not only the American healthcare system, but also the pharmaceutical industry.
Encouraging data was presented at the 61st Annual Scientific Meeting of the Gerontological Society of America, showcasing the success of Januvia, or sitagliptin, in studies completed among patients in the elderly population. Merck sponsored the aforementioned study, which focused on elderly patients who had type 2 diabetes. The patients who participated in this 24-week double-blind and randomized study involved roughly 206 patients between the ages of 65 and 96. The patients who were dosed with sitagliptin showed dramatic reductions in their blood sugar levels, without hypoglycemic symptoms.
LGM Pharma provides API sitagliptin for research and development purposes. Clients can be assured of continuous support throughout the R&D process, as well as quality API products.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.